106 related articles for article (PubMed ID: 2654849)
1. Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial.
Pan SH; Canafax DM; Le CT; Cipolle RJ; Uden DL; Warwick WJ
Pediatr Pulmonol; 1989; 6(3):172-9. PubMed ID: 2654849
[TBL] [Abstract][Full Text] [Related]
2. Effect of theophylline on lung function tests, sleep quality, and nighttime SaO2 in children with cystic fibrosis.
Avital A; Sanchez I; Holbrow J; Kryger M; Chernick V
Am Rev Respir Dis; 1991 Dec; 144(6):1245-9. PubMed ID: 1741534
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.
Murciano D; Auclair MH; Pariente R; Aubier M
N Engl J Med; 1989 Jun; 320(23):1521-5. PubMed ID: 2498658
[TBL] [Abstract][Full Text] [Related]
4. The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis.
Shapiro GG; Bamman J; Kanarek P; Bierman CW
Pediatrics; 1976 Nov; 58(5):740-3. PubMed ID: 790287
[TBL] [Abstract][Full Text] [Related]
5. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
Schmitt-Grohé S; Zielen S
Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
[TBL] [Abstract][Full Text] [Related]
6. Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function.
Larsen GL; Barron RJ; Landay RA; Cotton EK; Gonzalez MA; Brooks JG
Am J Dis Child; 1980 Dec; 134(12):1143-8. PubMed ID: 7446501
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
Valet SB; Schwartz RH; Brooks JG
Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
9. Theophylline disposition in cystic fibrosis.
Isles A; Spino M; Tabachnik E; Levison H; Thiessen J; MacLeod S
Am Rev Respir Dis; 1983 Apr; 127(4):417-21. PubMed ID: 6838048
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic obstructive pulmonary disease with two sustained-release theophylline preparations.
Giosue S; Bernocchi D; Parola D; Munno R; Mancini P
J Int Med Res; 1987; 15(6):352-60. PubMed ID: 3325318
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.
Knoppert DC; Spino M; Beck R; Thiessen JJ; MacLeod SM
Clin Pharmacol Ther; 1988 Sep; 44(3):254-64. PubMed ID: 3046811
[TBL] [Abstract][Full Text] [Related]
12. Oral theophylline disposition in cystic fibrosis.
Georgitis JW; Eigen H; Warner R; Gonzales MA
Ann Allergy; 1982 Mar; 48(3):175-7. PubMed ID: 7065481
[TBL] [Abstract][Full Text] [Related]
13. A comparative trial of the clinical efficacy and pharmacokinetics of 12-hour and 24-hour controlled release theophylline preparations in patients with chronic asthma.
Tinkelman DG; Miller E; Janky DG; Decouto J; Edelman L
Ann Allergy; 1985 Oct; 55(4):571-6. PubMed ID: 3901832
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity.
Sivan Y; Arce P; Eigen H; Nickerson BG; Newth CJ
J Allergy Clin Immunol; 1990 Mar; 85(3):649-54. PubMed ID: 2107242
[TBL] [Abstract][Full Text] [Related]
15. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
16. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
17. Increased physiological dead space during exercise after bronchodilation in cystic fibrosis.
Kusenbach G; Friedrichs F; Skopnik H; Heimann G
Pediatr Pulmonol; 1993 May; 15(5):273-8. PubMed ID: 8327285
[TBL] [Abstract][Full Text] [Related]
18. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.
Bleecker ER; Britt EJ
Am J Med; 1991 Oct; 91(4A):24S-27S. PubMed ID: 1835291
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study.
Alexander MR; Dull WL; Kasik JE
JAMA; 1980 Nov; 244(20):2286-90. PubMed ID: 7001056
[TBL] [Abstract][Full Text] [Related]
20. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin.
Gisclon LG; Curtin CR; Fowler CL; Williams RR; Hafkin B; Natarajan J
J Clin Pharmacol; 1997 Aug; 37(8):744-50. PubMed ID: 9378847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
